Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13376980 | 0.96 | RECQL (0.61) | RECQLTSHRFAAHEPHX2ALDH1A1 | |
| SCHEMBL2771342 | 0.94 | RECQL (0.63) | RECQLTSHRFAAHEPHX2ALDH1A1 | |
| SCHEMBL28279287 | 0.93 | FAAH (0.64) | RECQLFAAHEPHX2DNM1CASP2 | |
| SCHEMBL28920863 | 0.93 | FAAH (0.56) | RECQLTSHRFAAHEPHX2ALDH1A1 | |
| SCHEMBL28576359 | 0.93 | FAAH (0.64) | RECQLFAAHEPHX2DNM1CASP2 | |
| SCHEMBL28572453 | 0.93 | FAAH (0.64) | RECQLFAAHEPHX2DNM1CASP2 | |
| SCHEMBL13376978 | 0.91 | RECQL (0.65) | RECQLTSHRFAAHEPHX2ALDH1A1 | |
| SCHEMBL18724627 | 0.90 | EPHX2 (0.62) | RECQLTSHRFAAHEPHX2DNM1 | |
| SCHEMBL18782496 | 0.90 | EPHX2 (0.62) | RECQLTSHRFAAHEPHX2DNM1 | |
| SCHEMBL15399777 | 0.89 | TSHR (0.65) | RECQLTSHRFAAHEPHX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057446-B1 | ORGANIC COMPOUNDS HAVING TASTE-MODIFYING PROPERTIES | GIVAUDAN SA (CH) | 2017-12-06 | — | — | EP | disclosed |
| US-20160278408-A1 | Organic Compounds | GIVAUDAN S.A. (CH) | 2016-09-29 | — | — | US | disclosed |
| EP-3057446-A1 | ORGANIC COMPOUNDS | Givaudan S.A. (CH) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015050537-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160278408-A1 | Organic Compounds | CYC1, AOX1, OR10J3 | RECQL 2381/4885TSHR 3642/4885FAAH 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.